Nevertheless, the present results are in agreement with previous studies, showing no difference in insulin resistance following treatment with Eplerenone in obese and hypertensive subjects (Adachi et al., 2019), as well as on insulin resistance in metabolic syndrome (Hwang et al., 2015), but to the best of our knowledge, the effect of MR blockade, as a mono‐therapy, has not previously been investigated in individuals with type 2 diabetes. Here, NR3C2 is linked to metabolic syndrome.